Showing 2181-2190 of 2892 results for "".
- FDA Clears Wontech’s Sandro Dual Laserhttps://modernaesthetics.com/news/fda-clears-wontechs-sandro-dual-laser/2472905/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Industry Responds to COVID-19: E.T. Browne Drug Co., RealSelf, HydraFacial, Thrive Causemeticshttps://modernaesthetics.com/news/industry-responds-to-covid-19-dermyoung-coty-leo-pharma/2472903/E.T. Browne Drug Co. The manufacturer of Palmer' Cocoa Butter Formula and Coconut Oil Formula skin and hair care products is now producing medical-grade hand sanitizer to address widespread supply shortages in the wake of COVID-19. Initial production of the disinfectant sanit
- National Nurses Union Urges Congress to Ensure Healthcare Workers' Safety Against COVID-19https://modernaesthetics.com/news/national-nurses-union-urges-congress-to-ensure-healthcare-workers-safety-against-covid-19/2472898/National Nurses United, the largest union of registered nurses, is calling on Congress to mandate that the Occupational Safety and Health Administration promulgate an emergency temporary standard for health care workers in the third COVID-19 stimulus package currently being negotiated.
- Special Report: Dr. Jonathan Kaplan Offers Coronavirus Overviewhttps://modernaesthetics.com/news/special-report-dr-jonathan-kaplan-offers-coronavirus-overview/2472894/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less collateral damag
- BTL Introduces Emsella Applicator for Emsculpt Platformhttps://modernaesthetics.com/news/btl-introduces-emsella-applicator-for-emsculpt-platform/2472892/BTL is launching the new Emsella applicator with up to 2.5 Tesla (T) to treat all forms of male and female urinary incontinence. Building upon the existing clearances for Emsculpt for the abdomen, buttocks, thighs, arms and calves, the new Emsella applicator makes Emsculpt the first system to tre
- Dermatologists React to Threat of Coronavirus Pandemichttps://modernaesthetics.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic-1/2472891/Reports about COVID-19 are causing many dermatologists and aesthetic physicians to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a &l
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Get Ready for Allergan's New DTC Juvéderm Lips Campaignhttps://modernaesthetics.com/news/get-ready-for-allergans-new-dtc-juvederm-lips-campaign/2472882/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Au
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.